UpdatesPlus Alert - Live from EULAR 2014 - 14 Oral presentations to see tomorrow June 12th

As part of our EULAR coverage we have selected out a number of what we consider to be particularly interesting oral presentations relevant to the UpdatesPlus portfolio (for EULAR this includes RA; Lupus; Gout and PsA/AS).  

The presentations to be covered are indicated below.  We intend to cover these presentations and follow up later with full analysis of the data presented.  We will of course be covering posters as well.  Please feel free to pass this information on to your colleagues and if they wish to be placed on our mailing list please contact fiona.watts@leaddiscovery.co.uk 

Rheumatoid Arthritis

• ·     INDUCTION OF CLINICAL REMISSION FOLLOWED BY DRUG-FREE WITHDRAWAL WITH ABATACEPT COMBINATION AND MONOTHERAPY IN EARLY RA: RESULTS FROM THE AVERT STUDY OVER 18 MONTHS
• ·     ITOLIZUMAB, A HUMAN ANTI-CD6 MONOCLONAL ANTIBODY, FOR TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS OF A RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 STUDY
• ·     EFFECTS OF SARILUMAB PLUS MTX ON CLINICAL, RADIOGRAPHIC, AND FUNCTIONAL ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY
• ·     MRI RESULTS FROM THE AVERT STUDY: A RANDOMIZED, ACTIVE-CONTROLLED TRIAL TO EVALUATE INDUCTION OF REMISSION AND MAINTENANCE OF DRUG-FREE REMISSION USING ABATACEPT IN COMBINATION WITH METHOTREXATE OR AS MONOTHERAPY IN PATIENTS WITH EARLY RA
• ·     IDENTIFICATION OF GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE OPTIMA STUDY
• ·     WHEN DOES THE THERAPEUTIC WINDOW OF OPPORTUNITY IN RHEUMATOID ARTHRITIS CLOSE? A STUDY IN TWO EARLY RA COHORTS.
• ·     EARLY RESPONSE TO ETANERCEPT-METHOTREXATE INDUCTION THERAPY PREDICTS SUSTAINED REMISSION WITH REDUCED-DOSE COMBINATION REGIMEN IN THE PRIZE STUDY

 Lupus

• ·     EFFECTS OF ATACICEPT ON DISEASE ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: APRIL-SLE RANDOMIZED TRIAL
• ·    A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
• ·     OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOUS (SLE) PATIENTS TREATED WITH BELIMUMAB IN CLINICAL PRACTICE SETTINGS: RESULTS FROM THE OBSERVE STUDY IN GERMANY

 Psoriatic Arthritis

• ·     LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS WITH AND WITHOUT PRIOR ANTI-TUMOR NECROSIS FACTOR EXPOSURE: 96-WEEK OUTCOMES FROM THE RAPID-PSA TRIAL
• ·    APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENT IN MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS
• ·     USTEKINUMAB IS EFFECTIVE IN INHIBITING RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTEGRATED DATA ANALYSIS OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
• ·     IMPACT OF PERSISTENT MINIMAL DISEASE ACTIVITY ON LONG-TERM OUTCOMES IN PSORIATIC ARTHRITIS: RESULTS FROM 5 YEARS OF THE LONG TERM EXTENSION OF A RANDOMIZED, PLACEBO-CONTROLLED, STUDY